Literature DB >> 11500181

Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.

Y Fukunaga1, H Itoh, K Doi, T Tanaka, J Yamashita, T H Chun, M Inoue, K Masatsugu, N Sawada, T Saito, K Hosoda, H Kook, M Ueda, K Nakao.   

Abstract

Insulin resistance has been highlighted as a common causal factor for glucose intolerance, hypertension and dyslipidemia, all of which are cardiovascular risk factors. A new class of antidiabetic agents, thiazolidinediones (TZDs), has been developed and demonstrated to improve insulin sensitivity. TZDs are high affinity ligands for peroxisome proliferator-activated receptor gamma (PPARgamma), the crucial transcription factor for adipocytes. Recent studies showed that PPARgamma is also expressed in monocytes/macrophages and is suggested to be involved in atherosclerosis. We could detect PPARgamma gene transcript in several cultured endothelial cells (human aortic endothelial cells (HAoECs), human coronary artery endothelial cells (HCAECs), human umbilical vein endothelial cells (HUVECs) and bovine carotid artery endothelial cells (BAECs)) as well as human coronary arteries we examined. Since endothelial dysfunction is critical for atherosclerosis, we investigated the effects of TZDs, troglitazone (TRO) and pioglitazone (PIO), on endothelial cell growth and secretion of C-type natriuretic peptide (CNP), which we demonstrated as a novel endothelium-derived relaxing peptide, and endothelin (ET), a potent vasoconstrictor, using HAoECs, HCAECs, HUVECs and BAECs. When all these cultured endothelial cells were daily treated with TRO and PIO for 5 days, both TRO and PIO (10(-8)M) significantly stimulated (3)H-thymidine incorporation of all these endothelial cells. In contrast, higher dose of TRO and PIO (10(-5)M) significantly suppressed DNA synthesis. TRO and PIO also exerted the compatible effect on the increase of cell numbers. TRO and PIO significantly enhanced CNP secretion from BAECs. In contrast, ET secretion from BAECs was suppressed by both TRO and PIO in a dose-dependent manner. The results of the present study suggest that TZDs modulate endothelial functions, including regulation of endothelial cell growth and secretion of endothelium-derived vasoactive substances, which affect vascular tone and remodeling in the process of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500181     DOI: 10.1016/s0021-9150(01)00430-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  23 in total

Review 1.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

2.  Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism.

Authors:  M Artwohl; C Fürnsinn; W Waldhäusl; T Hölzenbein; G Rainer; A Freudenthaler; M Roden; S M Baumgartner-Parzer
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

Review 3.  Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.

Authors:  S Giannini; M Serio; A Galli
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

4.  Mixing of the old with the new: nanoparticle-mediated pioglitazone delivery to enhance therapeutic neovascularization.

Authors:  Calvin C Sheng; Charles C Hong
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10       Impact factor: 8.311

5.  Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.

Authors:  Ningning Wang; J David Symons; Hui Zhang; Zhanjun Jia; Frank J Gonzalez; Tianxin Yang
Journal:  Toxicol Pathol       Date:  2008-12-15       Impact factor: 1.902

6.  The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation.

Authors:  David E Green; Tamara C Murphy; Bum-Yong Kang; Jennifer M Kleinhenz; Cédric Szyndralewiez; Patrick Page; Roy L Sutliff; C Michael Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2012-08-16       Impact factor: 6.914

7.  Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

Authors:  Andreas M Beyer; Gary L Baumbach; Carmen M Halabi; Mary L Modrick; Cynthia M Lynch; Thomas D Gerhold; Shams M Ghoneim; Willem J de Lange; Henry L Keen; Yau-Sheng Tsai; Nobuyo Maeda; Curt D Sigmund; Frank M Faraci
Journal:  Hypertension       Date:  2008-02-19       Impact factor: 10.190

Review 8.  Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes.

Authors:  Toshikazu Yamanouchi
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

Review 9.  Metabolic and additional vascular effects of thiazolidinediones.

Authors:  Fabrice M A C Martens; Frank L J Visseren; Jacinthe Lemay; Eelco J P de Koning; Ton J Rabelink
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  The possible role of peroxisome proliferator-activated receptor gamma in heart failure.

Authors:  Natsuhiko Ehara; Koh Ono; Tatsuya Morimoto; Teruhisa Kawamura; Mitsuru Abe; Koji Hasegawa
Journal:  Exp Clin Cardiol       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.